title: Atypical paraneoplastic syndrome associated with anti-Yo antibodies.
abstract: OBJECTIVE
  Polyneuropathy, myopathy and spasticity have not been described as a manifestation of a neurologic paraneoplastic syndrome (NPS) associated with anti-Yo antibodies (anti-Yo).
  
  
  METHODS
  The patient is a 60-year-old woman with a history of ovarectomy, salpingectomy, hysterectomy and omentectomy because of ovarian cancer with peritoneal carcinosis. From May to September 1999, she received chemotherapy with carboplatin and docetaxel. In June 1999, weaknesses of the lower limbs began to appear. Neurologic investigation revealed bilateral ptosis with right-sided predominance, exaggerated deep tendon reflexes, discrete distal weakness, wasting of the upper limbs and diffuse weakness of the lower limbs. She had slight CK elevation, elevated lactate dehydrogenase and aldolase levels. Testing for anti-neuronal antibodies revealed high serum titers of antibodies against the cytoplasm of Purkinje cells, confirmed as anti-Yo by immunoblot with recombinant proteins. CSF investigations showed 12/3 cells and positive oligoclonal bands. MRI of the brain showed bilateral, old ischemic basal ganglia lesions exclusively. Visually evoked potentials gave prolonged P100 latencies bilaterally. Nerve conduction studies and electromyography revealed motor polyneuropathy of the lower limbs. Muscle biopsy from the right anterior tibial muscle showed non-specific myopathic features.
  
  
  CONCLUSIONS
  Polyneuropathy, myopathy and tetraspasticity may be the exclusive manifestations of an atypical NPS associated with anti-Yo. Anti-Yo may persist for years without relapse of the primary tumor.
authors.affiliation: Department of Neurology, Krankenanstalt Rudolfstiftung, Vienna, Austria. duarte@aonmail.at
authors.forename: J
authors.initials: J
authors.lastname: Finsterer
authors.forename: A
authors.initials: A
authors.lastname: Bodenteich
authors.forename: M
authors.initials: M
authors.lastname: Drlicek
mesh_terms: D000906:Antibodies / Q000097:blood / Q000276:immunology; D016190:Carboplatin / Q000627:therapeutic use; D000077143:Docetaxel; D004576:Electromyography; D004594:Electrophysiology; D005074:Evoked Potentials, Visual; D005260:Female; D006801:Humans; D015151:Immunoblotting; D008875:Middle Aged; D009128:Muscle Spasticity / Q000209:etiology*; D009135:Muscular Diseases / Q000209:etiology*; D010051:Ovarian Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000601:surgery; D017239:Paclitaxel / Q000031:analogs & derivatives* / Q000627:therapeutic use; D020362:Paraneoplastic Cerebellar Degeneration / Q000209:etiology* / Q000276:immunology / Q000503:physiopathology; D020364:Paraneoplastic Polyneuropathy / Q000209:etiology*; D011689:Purkinje Cells / Q000276:immunology; D043823:Taxoids
chemical_list: D000906:Antibodies; D043823:Taxoids; D000077143:Docetaxel; D016190:Carboplatin; D017239:Paclitaxel